BS_EFE4YEK3
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- os_event
- false
- age_years
- 9.14
- sex
- F
- race
- White
- new_clusters
- C4
- umap1_2d
- 3.161783756
- umap2_2d
- 5.769037075
- umap1_3d
- 0.937542128
- umap2_3d
- -0.063043747
- umap3_3d
- -2.60428835
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.570
- MYC_TARGETS_V1+0.440
- DNA_REPAIR+0.410
- SPERMATOGENESIS+0.330
- PANCREAS_BETA_CELLS+0.280
- MITOTIC_SPINDLE+0.270
- OXIDATIVE_PHOSPHORYLATION+0.270
- PROTEIN_SECRETION+0.130
- MTORC1_SIGNALING+0.090
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- INFLAMMATORY_RESPONSE-0.470
- INTERFERON_GAMMA_RESPONSE-0.470
- IL6_JAK_STAT3_SIGNALING-0.430
- ALLOGRAFT_REJECTION-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- MYOGENESIS-0.400
- COMPLEMENT-0.390
- COAGULATION-0.380
- TNFA_SIGNALING_VIA_NFKB-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_EFE4YEK3 | medulloblastoma | — | 0.948 |
| 2 | BS_GNV89A5P | medulloblastoma | — | 0.933 |
| 3 | SRR1797280 | — | cohortSC | 0.928 |
| 4 | BS_HF3RNN2T | medulloblastoma | — | 0.925 |
| 5 | BS_HKZENFDA | medulloblastoma | — | 0.923 |
| 6 | SRR13780268 | — | cohortSC | 0.923 |
| 7 | MDT-AP-0156 | Med | Medulloblastoma | 0.920 |
| 8 | BS_YETBN0RQ | medulloblastoma | — | 0.918 |
| 9 | BS_4CP4T22V | medulloblastoma | — | 0.917 |
| 10 | BS_1HQ76V6D | Embryonal tumors | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.410 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.270 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |